P313: How helpful are sleep studies in determining surgical need in infants with achondroplasia?

Le résumé fourni par la source

Results: A total of 8 studies were included in the analysis.Treatment with Bevacizumab demonstrated a significant reduction in epistaxis severity scores, with a pooled Mean Difference (MD) of 2.29 (95% CI: 1.16 to 3.43) in the random-effects model, indicating consistent improvements across most studies.Regarding hemoglobin levels, the common-effect model estimated a mean increase of 1.75 g/dL (95% CI: 1.74 to 1.77), suggesting a reliable overall benefit.These findings support the potential of Bevacizumab to reduce epistaxis severity and improve hemoglobin levels, although the variability across studies highlights the need for further research to confirm these effects.Conclusion: Bevacizumab appears to be an effective treatment for reducing epistaxis severity in patients with HTT, as evidenced by a significant improvement in severity scores.Additionally, the treatment showed a positive impact on hemoglobin levels.The findings suggest that Bevacizumab may improve the quality of life for patients with HHT; however, further high-quality studies are necessary to validate its efficacy and address the observed heterogeneity in outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.